Sana Biotechnology (SANA) Gains from Investment Securities (2020 - 2026)
Sana Biotechnology recorded quarterly Gains from Investment Securities of $2.6 million in Q1 2026, up 145.45% quarter-over-quarter from -$5.8 million in Q4 2025, and down 89.77% year-over-year from $25.6 million in Q1 2025.
Sana Biotechnology's Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 89.77% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $5.2 million (down 79.8% YoY), while the FY2025 annual figure was $22.9 million, down 8.46% from the prior year.
- Gains from Investment Securities came in at $2.6 million for Q1 2026 at Sana Biotechnology, up from -$5.8 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $30.3 million in Q2 2024 to a low of -$5.8 million in Q4 2025.
- A 5-year average of $8.0 million and a median of $3.6 million in 2024 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 900.0% in 2025 and fell as far as 1638.24% in 2025.
- Sana Biotechnology's Gains from Investment Securities stood at $3.4 million in 2022, then soared by 87.06% to $6.4 million in 2023, then tumbled by 94.2% to $374000.0 in 2024, then slumped by 1638.24% to -$5.8 million in 2025, then surged by 145.45% to $2.6 million in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $2.6 million, -$5.8 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.62 Mn |
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | -5.75 Mn |
| Dec 31, 2025 | -5.75 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 6.30 Mn |
| Jun 30, 2025 | 6.30 Mn |
| Mar 31, 2025 | 25.56 Mn |
| Mar 31, 2025 | 25.56 Mn |
| Dec 31, 2024 | 374,000.00 |
| Dec 31, 2024 | 374,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 30.27 Mn |
| Jun 30, 2024 | 30.27 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Dec 31, 2023 | 6.45 Mn |
| Dec 31, 2023 | 6.45 Mn |
| Sep 30, 2023 | 29.39 Mn |
| Sep 30, 2023 | 29.39 Mn |
| Jun 30, 2023 | 7.96 Mn |
| Jun 30, 2023 | 7.96 Mn |
| Mar 31, 2023 | 2.91 Mn |
| Mar 31, 2023 | 2.91 Mn |
| Dec 31, 2022 | 3.45 Mn |
| Dec 31, 2022 | 3.45 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Jun 30, 2022 | 970,000.00 |
| Jun 30, 2022 | 970,000.00 |
| Mar 31, 2022 | 8.05 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 821,000.00 |
| Dec 31, 2021 | 821,000.00 |
| Sep 30, 2021 | 8.50 Mn |
| Sep 30, 2021 | 8.50 Mn |
| Jun 30, 2021 | -7.20 Mn |
| Jun 30, 2021 | -7.20 Mn |
| Mar 31, 2021 | 15.78 Mn |
| Mar 31, 2021 | 15.78 Mn |
| Dec 31, 2020 | 52.59 Mn |
| Dec 31, 2020 | 52.59 Mn |
| Sep 30, 2020 | 2.30 Mn |
| Sep 30, 2020 | 2.30 Mn |
| Jun 30, 2020 | 5.70 Mn |
| Jun 30, 2020 | 5.70 Mn |
| Mar 31, 2020 | 14.27 Mn |
| Mar 31, 2020 | 14.27 Mn |